Temanogrel

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Temanogrel ( , ; developmental code name APD791) is a serotonin 5-HT 2A receptor antagonist and inverse agonist which is under development for the treatment of myocardial ischemia and Raynaud's disease. It was also being developed for arterial thrombosis and acute coronary syndromes, but development for the former use was suspended and development for the latter indication was discontinued. The drug is taken orally. Temanogrel is highly selective for the serotonin 5-HT 2A receptor, with more than 2,000-fold selectivity for this receptor over the serotonin 5-HT 2B and 5-HT 2C receptors and lack of activity at a variety of other G protein-coupled receptors (GPCRs). As of September 2022, it is in phase 2 clinical trials for myocardial ischemia and Raynaud's disease.

Temanogrel ( , ; developmental code name APD791) is a serotonin 5-HT 2A receptor antagonist and inverse agonist which is under development for the treatment of myocardial ischemia and Raynaud's disease. It was also being developed for arterial thrombosis and acute coronary syndromes, but development for the former use was suspended and development for the latter indication was discontinued. The drug is taken orally. Temanogrel is highly selective for the serotonin 5-HT 2A receptor, with more than 2,000-fold selectivity for this receptor over the serotonin 5-HT 2B and 5-HT 2C receptors and lack of activity at a variety of other G protein-coupled receptors (GPCRs). As of September 2022, it is in phase 2 clinical trials for myocardial ischemia and Raynaud's disease.

See also

Serotonin 5-HT 2A receptor antagonist

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1334185324 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.